Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801205 | 0.94 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1269394 | 0.88 | ALDH1A1 (0.42) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1269541 | 0.87 | ALDH1A1 (0.42) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1268643 | 0.86 | ALDH1A1 (0.41) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1269368 | 0.86 | PTGDR (0.39) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1269423 | 0.86 | ALDH1A1 (0.39) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1268539 | 0.86 | ALDH1A1 (0.40) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1268550 | 0.86 | ALDH1A1 (0.40) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1269543 | 0.86 | ALDH1A1 (0.41) | MAPTSMN1; SMN2POLBALDH1A1LMNA | |
| SCHEMBL1268859 | 0.86 | ALDH1A1 (0.39) | MAPTSMN1; SMN2POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893077-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1786782-B1 | BISARYL-SULFONAMIDES | AMGEN INC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221584-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2009-09-03 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544702-B2 | Bisaryl-sulfonamides | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060084802-A1 | Bisaryl-sulfonamides | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221584-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | MAPT 4602/4885SMN1; SMN2 4836/4885POLB 1629/4885 |
| US-20060084802-A1 | Bisaryl-sulfonamides | PPARD, PPARA, PPARG | MAPT 4602/4885SMN1; SMN2 4836/4885POLB 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.